273 related articles for article (PubMed ID: 32609958)
1. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.
Correll CU; Lauriello J
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609958
[TBL] [Abstract][Full Text] [Related]
2. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
Kane JM; McEvoy JP; Correll CU; Llorca PM
CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
Kane JM; Correll CU
J Clin Psychiatry; 2019 Sep; 80(5):. PubMed ID: 31536686
[TBL] [Abstract][Full Text] [Related]
4. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
5. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.
Kane JM; Kishimoto T; Correll CU
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S37-41. PubMed ID: 23849151
[TBL] [Abstract][Full Text] [Related]
6. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
Stevens GL; Dawson G; Zummo J
Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
[TBL] [Abstract][Full Text] [Related]
8. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
[TBL] [Abstract][Full Text] [Related]
9. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
[TBL] [Abstract][Full Text] [Related]
10. Rethinking the role of long-acting atypical antipsychotics in the community setting.
Altamura AC; Aguglia E; Bassi M; Bogetto F; Cappellari L; De Giorgi S; Fagiolini A; Ferrannini L; Girardi P
Int Clin Psychopharmacol; 2012 Nov; 27(6):336-49. PubMed ID: 22859065
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
Correll CU; Lauriello J
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505193
[TBL] [Abstract][Full Text] [Related]
12. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges.
Haddad PM; Correll CU
Expert Opin Pharmacother; 2023 Mar; 24(4):473-493. PubMed ID: 36919576
[TBL] [Abstract][Full Text] [Related]
13. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
14. Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?
Perkins DO
J Clin Psychiatry; 2017; 78(9):e1431. PubMed ID: 29345879
[TBL] [Abstract][Full Text] [Related]
15. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.
Heres S; Lambert M; Vauth R
Eur Psychiatry; 2014 Nov; 29 Suppl 2():1409-13. PubMed ID: 25455704
[TBL] [Abstract][Full Text] [Related]
16. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.
Suzuki T
Expert Opin Drug Deliv; 2016; 13(2):253-64. PubMed ID: 26636244
[TBL] [Abstract][Full Text] [Related]
17. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery.
Arango C; Fagiolini A; Gorwood P; Kane JM; Diaz-Mendoza S; Sahota N; Correll CU
BMC Psychiatry; 2023 Jun; 23(1):453. PubMed ID: 37344763
[TBL] [Abstract][Full Text] [Related]
18. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.
Correll CU
J Clin Psychiatry; 2014 Nov; 75(11):e29. PubMed ID: 25470105
[TBL] [Abstract][Full Text] [Related]
19. Long-acting injectable antipsychotics: recommendations for clinicians.
Malla A; Tibbo P; Chue P; Levy E; Manchanda R; Teehan M; Williams R; Iyer S; Roy MA
Can J Psychiatry; 2013 May; 58(5 Suppl 1):30S-5S. PubMed ID: 23945065
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care.
Lauriello J; Perkins DO
J Clin Psychiatry; 2019 Feb; 80(1):. PubMed ID: 30786179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
